ADRB3

(redirected from Beta-3 adrenoceptor)

ADRB3

A gene on chromosome 8p12 that encodes beta-1-adrenergic receptor, a member of the G protein-coupled receptor superfamily, which mediates catecholamine-induced activation of adenylate cyclase. ADRB3 is located primarily in adipose tissue and is involved in regulating lipolysis and thermogenesis.

References in periodicals archive ?

- US-based specialty pharmaceutical company Velicept Therapeutics' next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder, the company said.

Solabegron is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.

Velicept Therapeutics Touts Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder

reviews for anti-muscarinic agents and beta-3 adrenoceptor agonist

CUA guideline on adult overactive bladder

Its lead product, solabegron, is a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome.

Velicept Therapeutics Raises an Additional USD 15m in series B Round, Initiates Phase 2b Study, Receives Issuance of US Patent

Oral pharmacotherapies for the treatment of OAB include antimuscarinics such as solifenacin and the beta-3 adrenoceptor ([beta]3AR) agonist mirabegron.

Beta-3 adrenoceptor expression in the human urinary bladder nerve fibers.

What's new in functional urology research?

- Malvern, Pennsylvania-based specialty pharmaceutical company Velicept Therapeutics has commenced the first of two Phase 2b clinical studies of solabegron, a highly potent and selective beta-3 adrenoceptor agonist being investigated for overactive bladder and irritable bowel syndrome, the company said.

Velicept Therapeutics Begins Enrollment in Study of Twice-daily Solabegron for Treatment of Overactive Bladder